{
    "2018-05-04": [
        [
            {
                "time": "2018-04-25",
                "original_text": "Pharma Stock Roundup: Mixed Q1 for MRK, PFE, FDA Nod for Kymriah's 2nd Indication",
                "features": {
                    "keywords": [
                        "MRK",
                        "PFE",
                        "FDA",
                        "Kymriah",
                        "Indication"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-27",
                "original_text": "Aduro (ADRO) Q1 Loss Narrower Than Expected, Revenues Beat",
                "features": {
                    "keywords": [
                        "ADRO",
                        "Q1",
                        "Loss",
                        "Narrower",
                        "Revenues",
                        "Beat"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-03",
                "original_text": "FDA approves Novartis combo therapy for aggressive type of thyroid cancer",
                "features": {
                    "keywords": [
                        "FDA",
                        "Novartis",
                        "combo",
                        "therapy",
                        "thyroid",
                        "cancer"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-04",
                "original_text": "Prolia Revenue Grew 16% in 1Q18",
                "features": {
                    "keywords": [
                        "Prolia",
                        "Revenue",
                        "Grew",
                        "16%",
                        "1Q18"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "3 “High Yield Leaders” to Buy for 5% to 12% Payouts",
                "features": {
                    "keywords": [
                        "High",
                        "Yield",
                        "Leaders",
                        "Buy",
                        "Payouts"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "dividend stocks"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-15",
                "original_text": "Kyprolis Is Expected to Boost Amgen’s Revenue Growth",
                "features": {
                    "keywords": [
                        "Kyprolis",
                        "Amgen",
                        "Revenue",
                        "Growth"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-01",
                "original_text": "The Swiss Stock Market",
                "features": {
                    "keywords": [
                        "Swiss",
                        "Stock",
                        "Market"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general market"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}